Endocrine Abstracts

Introduction: Data on the desirable Vitamin D (VitD) levels and VitD-supplementation during pregnancy are very controversial and thus everyday practice varies a lot. In our study the aim is to record VitD levels, as well as the VitD-supplementation and their association with pregnancy outcomes in women referred to our center in the second and third trimester of pregnancy.

Methods: We studied 193 pregnant women mean age 30.34±7.07 years old. In each patient we measured 25(OH) Vitamin D3 levels at the second and third trimester of pregnancy (reference range for 25(OH) Vitamin D3 is 20-32 ng/ml, and VitD deficiency is <20 ng/ml). We also recorded the VitD-supplementation, gestational age at delivery (GAd), childbirth type and offspring birthweight (ofBW).

Results: Baseline mean gestational age (GA) was 27.18±6.78 weeks and mean 25(OH) Vitamin D3 levels were 20.64±11.80 ng/ml. 133 out of 193 (68.91%) women had normal 25(OH) Vitamin D3 (ND3, mean levels 23.35±13.19 ng/ml), and 60 out of 193 (31.08%) had 25(OH) Vitamin D3 deficiency (DD3, mean levels 14.76±3.79 ng/ml.) ND3 women had mean age 30.24±7.28 years old, mean GA 27.84±6.23 weeks, 34/ND3 (25.56%) were not on VitD-supplementation, 67/ND3 (50.37%) were on 200-800 IU VitD-supplementation daily, 19/ND3 (14.28%) on 1000-1800 IU/daily and 13/ND3 (9.77%) on 2000-4000 IU/daily. 35 of ND3 (26.21%) were on calcium-supplementation (500 mg/daily). In ND3 the mean GAd was 37.98±1.32 weeks, mean ofBW was 3034.34±587.44 gr and 53/ND3 (39.84%) had a caesarean section. DD3 women had mean age 30.56±6.55 years old, mean GA 25.73±7.70 weeks, 6/DD3 (10%) had VitD-supplementation >4000 IU/daily, 21/DD3 (35%) were on 2000-4000 IU/daily, 9/DD3 (15%) on 1000-1800 IU/daily, 18/DD3 (30%) on 200-800 IU/daily and 6/DD3 (10%) were not on VitD-supplementation. 14 of DD3 (23.33%) were on calcium-supplementation (500 mg/daily). In DD3 the mean GAd was 37.57±1.83 weeks, mean ofBW was 3094.76±587.22gr and 25/DD3 (41.66%) had a caesarean section.

Conclusion: VitD-supplementation doses during pregnancy defer - despite the existing guidelines - depending on the Obstetrician. Current recommendation suggest that women with normal VitD levels require VitD-supplementation with 400-600 IU/daily, whereas women with VitD deficiency a higher dose of 1000-4000 IU/daily. In our study pregnant women who referred to us at the second and third trimester with normal VitD levels were on no or on the minimum daily dose of VitD-supplementation (200-800 IU) and those with VitD deficiency were on the maximum daily dose (2000-4000 IU) - more or less complying with the recommendation. No significant differences on pregnancy outcomes were reported between the two groups.